{
    "clinical_study": {
        "@rank": "100830", 
        "acronym": "HALT-PKD", 
        "arm_group": [
            {
                "arm_group_label": "ACE-I + placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg"
            }, 
            {
                "arm_group_label": "ACE-I + ARB", 
                "arm_group_type": "Active Comparator", 
                "description": "ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg"
            }
        ], 
        "brief_summary": {
            "textblock": "The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the\n      progression of cystic disease and on the decline in renal function in autosomal dominant\n      kidney disease (ADPKD) will be assessed in two simultaneous multicenter randomized clinical\n      trials targeting different levels of kidney function: 1) early disease defined by GFR >60\n      mL/min/1.73 m2 (Study A); and 2) moderately advanced disease defined by GFR 25-60\n      mL/min/1.73 m2 (Study B). Participants will be recruited and enrolled, either to Study A or\n      B, over the first three years. Participants enrolled in Study B will be followed for\n      five-to-eight years, with the average length of follow-up being six and a half years."
        }, 
        "brief_title": "HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney, Polycystic", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Polycystic Kidney Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "* Specific Aim of Study B\n\n      To study the effects of ACE-I/ARB combination therapy as compared to ACE-I monotherapy in\n      the setting of standard blood pressure control (110-130/80 mm Hg) on the time to a 50%\n      reduction of baseline eGFR, ESRD or death, in hypertensive individuals with moderate renal\n      insufficiency (GFR 25-60 mL/min/1.73m2).\n\n      * Hypothesis to be tested in Study B\n\n      In hypertensive ADPKD individuals with moderate renal insufficiency (GFR 25-60 mL/min/1.73\n      m2), intensive blockade of the RAAS using combination ACE-I/ARB therapy will slow the\n      decline in kidney function over ACE-I monotherapy, independent of standard blood pressure\n      control (110-130/80 mm Hg)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of ADPKD.\n\n          -  Age 15-49 (Study A); Age 18-64 (Study B).\n\n          -  GFR >60 mL/min/1.73 m2 (Study A); GFR 25-60 mL/min/1.73 m2 (Study B).\n\n          -  BP \u2265130/80 or receiving treatment for hypertension.\n\n          -  Informed Consent.\n\n        Exclusion Criteria:\n\n          -  Pregnant/intention to become pregnant in 4-6 yrs.\n\n          -  Documented renal vascular disease.\n\n          -  Spot urine albumin-to-creatinine ratio of >0.5 (Study A) or \u22651.0 (Study B) and/or\n             findings suggestive of kidney disease other than ADPKD.\n\n          -  Diabetes requiring insulin or oral hypoglycemic agents / fasting serum glucose of\n             >126 mg/dl / random non-fasting glucose of >200 mg/dl.\n\n          -  Serum potassium >5.5 mEq/L for participants currently on ACE-I or ARB; >5.0 mEq/L for\n             participants not currently on ACE-I or ARB.\n\n          -  History of angioneurotic edema or other absolute contraindication for ACE-I or ARB.\n             Intolerable cough associated with ACE-I is defined as a cough developing within six\n             months of initiation of ACE-I in the absence of other causes and resolving upon\n             discontinuation of the ACE-I.\n\n          -  Indication (other than hypertension) for \u03b2-blocker or calcium channel blocker therapy\n             (e.g. angina, past myocardial infarction, arrhythmia), unless approved by the site\n             principal investigator. (PI may choose to accept an individual who is on only a small\n             dose of one of these agents and would otherwise be eligible.)\n\n          -  Systemic illness necessitating NSAIDs, immunosuppressant or immunomodulatory\n             medications.\n\n          -  Systemic illness with renal involvement.\n\n          -  Hospitalized for acute illness in past 2 months.\n\n          -  Life expectancy <2 years.\n\n          -  History of non-compliance.\n\n          -  Unclipped cerebral aneurysm >7mm diameter.\n\n          -  Creatine supplements within 3 months of screening visit.\n\n          -  Congenital absence of a kidney (also total nephrectomy for Study B).\n\n          -  Known allergy to sorbitol or sodium polystyrene sulfonate.\n\n          -  Exclusions specific to MR imaging (Study A)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "486", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885559", 
            "org_study_id": "DK62401-PKD-TN (IND)"
        }, 
        "intervention": [
            {
                "arm_group_label": "ACE-I + placebo", 
                "description": "Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.", 
                "intervention_name": "Lisinopril and Placebo", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ACE-I", 
                    "ACE", 
                    "Ace-Inhibitor", 
                    "Lisinopril", 
                    "ARB", 
                    "Placebo"
                ]
            }, 
            {
                "arm_group_label": "ACE-I + ARB", 
                "description": "Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.", 
                "intervention_name": "Lisinopril and Telmisartan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ACE-I", 
                    "ACE", 
                    "Ace-Inhibitor", 
                    "Lisinopril", 
                    "ARB", 
                    "Telmisartan"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Angiotensin-Converting Enzyme Inhibitors", 
                "Lisinopril", 
                "Telmisartan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "polycystic kidney disease", 
            "polycystic", 
            "kidney", 
            "disease", 
            "adpkd", 
            "halt", 
            "pkd", 
            "blood pressure", 
            "bp", 
            "hypertension", 
            "renal", 
            "renin-angiotensin-aldosterone-system", 
            "RAAS"
        ], 
        "lastchanged_date": "June 20, 2013", 
        "link": [
            {
                "description": "HALT PKD Home Page", 
                "url": "http://www.pkd.wustl.edu/pkdtn"
            }, 
            {
                "description": "Polycystic Kidney Disease Foundation Website", 
                "url": "http://www.pkdcure.org"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver (Aurora)", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "800045"
                    }, 
                    "name": "University of Colorado Health Sciences Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "University of Kansas Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "Tufts University-New England Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Foundation"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Polycystic Kidney Disease-Treatment Network", 
        "overall_official": [
            {
                "affiliation": "University of Colorado, Denver", 
                "last_name": "Robert Schrier, M.D.", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Emory University", 
                "last_name": "Arlene Chapman, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Tufts University-New England Medical Center", 
                "last_name": "Ronald Perrone, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Mayo Clinic", 
                "last_name": "Vicente Torres, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                "last_name": "Marva Moxey-Mims, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University of Pittsburgh", 
                "last_name": "Charity G Moore, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United States: Federal Government"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to 50% reduction of baseline eGFR, ESRD (initiation of dialysis or preemptive transplant), or death.", 
            "safety_issue": "No", 
            "time_frame": "Patients followed for 5-8 years with average of 6.5 years follow up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885559"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Albuminuria", 
                "safety_issue": "No", 
                "time_frame": "up to 8 years (annually assessed)"
            }, 
            {
                "measure": "Aldosterone", 
                "safety_issue": "No", 
                "time_frame": "up at 8 years (annually assessed)"
            }, 
            {
                "measure": "Hospitalizations", 
                "safety_issue": "No", 
                "time_frame": "up to 8 years"
            }, 
            {
                "measure": "Cardiovascular Hospitalizations", 
                "safety_issue": "No", 
                "time_frame": "up to 8 years"
            }, 
            {
                "measure": "Quality of Life Physical Component", 
                "safety_issue": "No", 
                "time_frame": "up to 8 years (annually assessed)"
            }, 
            {
                "measure": "Quality of Life Mental Component Summary", 
                "safety_issue": "No", 
                "time_frame": "up to 8 years (annually assessed)"
            }, 
            {
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "up to 8 years (annually assessed)"
            }
        ], 
        "source": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Boehringer Ingelheim", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Merck Sharp & Dohme Corp.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Polycystic Kidney Disease Foundation", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}